Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Netrin-1 is upregulated in some human cancers, enabling tumor cells to evade apoptosis via interaction with UNC5 homologs (UNC5H).
• The UNC5H family of dependence receptors plays a crucial role in triggering programmed cell death in response to netrin family ligands.

Purpose of the Study:

• To identify the specific domains involved in the netrin-1/UNC5H interaction.
• To develop a therapeutic antibody targeting the netrin-1/UNC5H pathway.
• To evaluate the efficacy of this antibody, alone and in combination with epigenetic drugs, for cancer treatment.

Main Methods:

• Protein domain mapping to identify the netrin-1 V-2 domain's role in binding UNC5H2 Ig1/Ig2 domains.
• Generation and characterization of a humanized anti-netrin-1 monoclonal antibody.
• In vitro studies assessing the antibody's ability to disrupt netrin-1/UNC5H2 interaction and induce tumor cell death.
• Preclinical evaluation of combination therapy with epigenetic drugs like decitabine.

Main Results:

• The V-2 domain of netrin-1 was identified as critical for its interaction with the Ig1/Ig2 domains of UNC5H2.
• A humanized anti-netrin-1 antibody was successfully generated, capable of blocking the netrin-1/UNC5H2 interaction.
• The antibody induced apoptosis in netrin-1-expressing tumor cells in vitro.
• Combination therapy with the anti-netrin-1 antibody and decitabine demonstrated potential efficacy in tumors with low or no netrin-1 expression.

Conclusions:

• The netrin-1 V-2 domain is essential for binding to UNC5H2, presenting a therapeutic target.
• A humanized anti-netrin-1 antibody is a promising drug candidate for cancer therapy by reactivating apoptosis.
• Combination strategies involving this antibody and epigenetic drugs may broaden therapeutic applications to a wider range of tumors.